

Andrew D Zelenetz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7852736/andrew-d-zelenetz-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

229
papers

18,973
citations

61
h-index

137
g-index

237
ext. papers

22,504
ext. citations

4.2
avg, IF

6.16
L-index

#	Paper	IF	Citations
229	The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma.. <i>Leukemia and Lymphoma</i> , 2022 , 1-10	1.9	1
228	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.. <i>Blood Cancer Journal</i> , 2022 , 12, 29	7	1
227	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 2529-2529	2.2	
226	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). <i>Blood</i> , 2021 , 138, 2447-2447	2.2	
225	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. <i>Blood</i> , 2021 , 138, 2513-2513	2.2	
224	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. <i>Blood</i> , 2021 , 138, 4578-4578	2.2	
223	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021 , 8, e879-e890	14.6	13
222	Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients. <i>Blood Advances</i> , 2021 , 5, 1830-1836	7.8	4
221	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021 , 11, 113	7	6
220	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2257-2265	2.2	6
219	Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. <i>American Journal of Hematology</i> , 2021 , 96, 1211-1222	7.1	1
218	Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. <i>Blood Advances</i> , 2021 , 5, 2879-2889	7.8	7
217	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021 , 137, 39-48	2.2	10
216	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2021 , 137, 600-609	2.2	28
215	Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. <i>Blood Advances</i> , 2021 , 5, 345-351	7.8	1
214	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. <i>Blood Advances</i> , 2021 , 5, 4185-4197	7.8	2
213	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3109-3117	2.2	18

212	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020 , 135, 2224-2234	2.2	37
211	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020 , 26, 3589-3596	12.9	43
210	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020 , 126, 78-90	7.5	14
209	Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era. <i>Blood</i> , 2020 , 136, 36-38	2.2	0
208	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. <i>Blood</i> , 2020 , 136, 11-12	2.2	2
207	Evolving Treatment Patterns in Chronic Lymphocytic Leukemia Among Experts and Community Practitioners: Analysis of an Online Decision Support Tool. <i>Blood</i> , 2020 , 136, 41-42	2.2	
206	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020 , 136, 37-38	2.2	0
205	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020 , 136, 39-40	2.2	2
204	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 17-18	2.2	5
203	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 46-47	2.2	2
202	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020 , 136, 50-51	2.2	2
201	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020 , 136, 1134-1143	2.2	132
200	Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2939-2946	1.9	1
199	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020 , 10, 74	7	28
198	Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy. <i>British Journal of Haematology</i> , 2020 , 191, 326-328	4.5	
197	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020 , 4, 3977-3989	7.8	30
196	Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2020 , 34, 3047-3049	10.7	55
195	Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 749-756.e1	2	2

194	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1391-1402	2.2	109
193	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019 , 133, 1964-1976	2.2	72
192	Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. <i>Haematologica</i> , 2019 , 104, e163-e166	6.6	10
191	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1790-1799	2.2	156
190	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019 , 133, 2121-2129	2.2	31
189	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. <i>Lancet Haematology</i> , 2019 , 6, e366-e374	14.6	36
188	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 2834-2834	2.2	1
187	Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT). <i>Blood</i> , 2019 , 134, 2826-2826	2.2	2
186	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019 , 134, 502-502	2.2	4
185	Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients. <i>Blood</i> , 2019 , 134, 1758-1758	2.2	1
184	ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood</i> , 2019 , 134, 5244-5244	2.2	2
183	High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 2837-2837	2.2	4
182	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 1555-1555	2.2	2
181	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution. <i>Blood</i> , 2019 , 134, 22-22	2.2	3
180	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. <i>Blood</i> , 2019 , 134, 1619-1619	2.2	2
179	NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 650-661	7.3	71
178	Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019 , 134, 4724-4724	2.2	2
177	Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience. <i>Blood</i> , 2019 , 134, 2850-2850	2.2	

176	Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment Selection. <i>Blood</i> , 2019 , 134, 4299-4299	2.2	
175	Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 2904-2904	2.2	0
174	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019 , 3, 1568-1573	7.8	18
173	Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. <i>Health and Quality of Life Outcomes</i> , 2019 , 17, 173	3	3
172	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1438-1446	1.9	11
171	Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. <i>Blood</i> , 2019 , 133, 137-146	2.2	59
170	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 894-903	1.9	7
169	Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. <i>British Journal of Haematology</i> , 2019 , 184, 660-663	4.5	27
168	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1396-1407	59.2	780
167	A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. <i>Blood</i> , 2018 , 131, 1805-1808	2.2	36
166	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018 , 8, 60	7	17
165	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1163-1171	4.7	72
164	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , 2017 , 18, 297-311	21.7	173
163	Chronic Lymphocytic Leukemia: Individualizing Treatment Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 713-715	7.3	4
162	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 4119-4126	12.9	13
161	Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. <i>British Journal of Haematology</i> , 2017 , 176, 591-599	4.5	35
160	Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2017 , 130, 2196-2203	2.2	75
159	[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. <i>Leukemia and Lymphoma</i> , 2017 , 58, 809-815	1.9	5

158	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Blood</i> , 2017 , 130, 654-654	2.2	2
157	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016 , 128, 1458-64	2.2	57
156	The Role of Biosimilars. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 626-9	7.3	5
155	Diffuse Large B-Cell Lymphoma Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 196-231	7.3	60
154	Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. <i>American Journal of Hematology</i> , 2016 , 91, 770-5	7.1	19
153	Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 728-34	8.9	37
152	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. <i>Blood</i> , 2016 , 128, 1777-1777	2.2	1
151	Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). <i>Blood</i> , 2016 , 128, 1778-1778	2.2	3
150	Outcome of Initial Observation in Mantle Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1803-1803	2.2	2
149	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. <i>Blood</i> , 2016 , 128, 2955-2955	2.2	3
148	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. <i>Blood</i> , 2016 , 128, 2991-2991	2.2	18
147	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. <i>Blood</i> , 2016 , 128, 469-469	2.2	73
146	Analysis of an Online Decision Support Tool for Chronic Lymphocytic Leukemia: Disparities in Treatment Selection Between Experts and Community Practitioners. <i>Blood</i> , 2016 , 128, 5958-5958	2.2	
145	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. <i>Blood</i> , 2016 , 128, 4119-4119	2.2	
144	Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma. <i>Blood</i> , 2016 , 128, 4115-4115	2.2	
143	MYC-Dependent PI3K and MCL-1 Feedbacks Attenuate BET Inhibitors Activity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 294-294	2.2	
142	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. <i>Cancer</i> , 2016 , 122, 559-64	6.4	49
141	The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≥ 2 months. <i>British Journal of Haematology</i> , 2016 , 173, 260-4	4.5	9

140	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1067-79	7.3	80
139	High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1274-1281	7.3	6
138	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016 , 127, 2375-90	2.2	4080
137	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016 , 128, 1112-20	2.2	119
136	Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. <i>Haematologica</i> , 2016 , 101, 1237-1243	6.6	31
135	Management of adverse events associated with idelalisib treatment: expert panel opinion. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2779-86	1.9	221
134	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2516-22	2.2	438
133	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1293-1298	4.4	12
132	Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. <i>Radiology</i> , 2015 , 277, 518-26	20.5	16
131	Emerging treatment options for B-cell lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 666-9	7.3	3
130	Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2015 , 171, 776-83	4.5	23
129	Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. <i>British Journal of Haematology</i> , 2015 , 170, 85-95	4.5	39
128	Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2015 , 125, 2579-81	2.2	81
127	Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e113-5	2	2
126	Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2015 , 168, 663-70	4.5	25
125	Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. <i>Blood</i> , 2015 , 126, LBA-5-LBA-5	2.2	16
124	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. <i>Blood</i> , 2015 , 126, 2668-2668	2.2	
123	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 2691-2691	2.2	

122	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015 , 126, 3655-3655	5.2	1
121	Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2014 , 370, 997-1007	59.2	1303
120	Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. <i>Cancer</i> , 2014 , 120, 1993-9	6.4	26
119	Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 2004-9	4.7	41
118	Diffuse Large B-Cell Lymphoma 2014 , 263-269		
117	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood</i> , 2014 , 123, 837-42	2.2	517
116	Non-Hodgkin's lymphomas, version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1282-303	7.3	103
115	Non-Hodgkin's lymphomas, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 916-46	7.3	31
114	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014 , 124, 2354-61	2.2	306
113	Surveillance imaging for lymphoma: pros and cons. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e388-95	7.1	9
112	Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells. <i>PLoS ONE</i> , 2014 , 9, e79987	3.7	8
111	Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma. <i>British Journal of Haematology</i> , 2014 , 164, 646-52	4.5	5
110	A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 354-60	4.7	28
109	A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients \geq 5 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2014 , 124, 1986-1986	2.2	21
108	Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG [®]) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. <i>Blood</i> , 2014 , 124, 330-330	2.2	54
107	The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 701-7	8.8	2
106	Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 456-60	2.2	144
105	Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 106-11	2	182

104	Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 8-14	2	58
103	Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. <i>Cancer</i> , 2013 , 119, 3662-71	6.4	51
102	18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2163-7	1.9	48
101	Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. <i>British Journal of Haematology</i> , 2013 , 163, 487-95	4.5	53
100	Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2155-62	1.9	9
99	Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform. <i>Blood</i> , 2013 , 122, 1761-1761	2.2	1
98	PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study. <i>Blood</i> , 2013 , 122, 4245-4245	2.2	1
97	Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study. <i>Blood</i> , 2013 , 122, 510-510	2.2	4
96	Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. <i>Blood</i> , 2013 , 122, 640-640	2.2	6
95	A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients. <i>Blood</i> , 2013 , 122, 3058-3058	2.2	
94	Excellent Outcomes For Limited-Stage Diffuse Large B-Cell Lymphoma In The Rituximab Era: A Retrospective Analysis From Memorial Sloan-Kettering Cancer Center. <i>Blood</i> , 2013 , 122, 3030-3030	2.2	
93	Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. <i>Blood</i> , 2012 , 119, 2093-9	2.2	72
92	Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. <i>Blood</i> , 2012 , 119, 1665-70	2.2	191
91	Hepatitis B virus management to prevent reactivation after chemotherapy: a review. <i>Supportive Care in Cancer</i> , 2012 , 20, 2999-3008	3.9	25
90	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. <i>Haematologica</i> , 2012 , 97, 758-65	6.6	134
89	Non-Hodgkin's Lymphomas, version 3.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 1487-98	7.3	28
88	Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. <i>Cancer</i> , 2012 , 118, 2944-51	6.4	63
87	High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1113-6	1.9	34

86	Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3368-75	2.2	128
85	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. <i>Blood</i> , 2012 , 120, 1618-1618	2.2	2
84	An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.. <i>Blood</i> , 2012 , 120, 2656-2656	2.2	
83	Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.. <i>Blood</i> , 2012 , 120, 2669-2669 ^{3,2}		
82	Evaluation of Dual Tracer (FLT and FDG) PET Imaging As Part of Risk-Adapted Therapy for Patients with Advanced Stage Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2012 , 120, 792-792	2.2	
81	Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN. <i>Blood</i> , 2012 , 120, 1610-1610		
80	Tumor Associated Macrophage Expression, CD163, Is Associated with Poorer Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012 , 120, 1583-1583	2.2	
79	Non-Hodgkin's lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 484-560	5.6	47
78	Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1188-99	1.9	30
77	Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. <i>Clinical Cancer Research</i> , 2011 , 17, 2493-501 ^{12,9}	12.9	21
76	Electronic Chemotherapy Order Entry: A Major Cancer Center's Implementation. <i>Journal of Oncology Practice</i> , 2011 , 7, 213-8	3.1	10
75	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1799-807	16.6	95
74	Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience. <i>Blood</i> , 2011 , 118, 2688-2688	2.2	4
73	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. <i>Journal of Cell Biology</i> , 2011 , 194, i9-i9	7.3	
72	High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. <i>British Journal of Haematology</i> , 2010 , 148, 890-7	4.5	70
71	Reply to A. Höttnann et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e490-e491	2.2	1
70	Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1896-903	2.2	254
69	Reply to M.E. Juweid et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e721-e722	2.2	

68	Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. <i>Clinical Cancer Research</i> , 2010 , 16, 719-26	12.9	40
67	NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 288-334	7.3	185
66	Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2010 , 116, 4934-7	2.2	183
65	Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2010 , 116, 1793-1793	2.2	7
64	Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. <i>Journal of Clinical Oncology</i> , 2009 , 27, 491-7	2.2	62
63	Follicular lymphoma in the United States: first report of the national LymphoCare study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1202-8	2.2	230
62	Phase II-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4357-64	2.2	143
61	Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. <i>British Journal of Haematology</i> , 2009 , 145, 34-8	4.5	61
60	Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2009 , 146, 158-63	4.5	114
59	Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. <i>British Journal of Haematology</i> , 2009 , 146, 652-5	4.5	42
58	Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1538-42	4.7	29
57	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009 , 113, 4834-40	2.2	718
56	Overview of lymphoma diagnosis and management. <i>Radiologic Clinics of North America</i> , 2008 , 46, 175-98, vii	2.3	69
55	Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1858-64	2.2	39
54	Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5107-12	2.2	66
53	Synchronous presentation of systemic and brain non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2370-3	1.9	3
52	Sequential Chemotherapy Followed by High Dose Therapy and Autologous Stem Cell Rescue for Mantle Cell Lymphoma: Impact of MIB-1 on Outcome. <i>Blood</i> , 2008 , 112, 3759-3759	2.2	
51	FDG-PET lymphoma demonstration project invitational workshop. <i>Academic Radiology</i> , 2007 , 14, 330-9	4.3	25

50	Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. <i>Cancer</i> , 2007 , 110, 2528-34	6.4	44
49	Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. <i>British Journal of Haematology</i> , 2007 , 139, 425-8	4.5	77
48	Automated matching and segmentation of lymphoma on serial CT examinations. <i>Medical Physics</i> , 2007 , 34, 55-62	4.4	10
47	Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma.. <i>Blood</i> , 2007 , 110, 603-603	2.2	5
46	Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival. <i>Blood</i> , 2007 , 110, 1280-1280	2.2	
45	Outcomes for Patients Who Fail High Dose Chemoradiotherapy and Autologous Stem Cell Rescue for Relapsed and Primary Refractory Hodgkin Lymphoma.. <i>Blood</i> , 2007 , 110, 1649-1649	2.2	
44	Will radioimmunotherapy survive?. <i>Clinical Advances in Hematology and Oncology</i> , 2007 , 5, 782-4	0.6	1
43	Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2006 , 24, 166-73	2.2	358
42	Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1575-81	2.2	136
41	Marker-controlled watershed for lymphoma segmentation in sequential CT images. <i>Medical Physics</i> , 2006 , 33, 2452-60	4.4	54
40	Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. <i>Blood</i> , 2006 , 107, 2477-85	2.2	72
39	Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2006 , 134, 202-7	4.5	97
38	Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment.. <i>Blood</i> , 2006 , 108, 3057-3057	2.2	4
37	Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.. <i>Blood</i> , 2006 , 108, 532-532	2.2	20
36	The Non-Hodgkin Lymphomas 2006 , 1256-1284		
35	Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006 , 4, 258-310	7.3	30
34	Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. <i>Blood</i> , 2005 , 105, 4576-82	2.2	138
33	Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. <i>Blood</i> , 2005 , 106, 3383-5	2.2	62

32	Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. <i>British Journal of Haematology</i> , 2005 , 130, 691-9	4.5	104
31	R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. <i>Leukemia and Lymphoma</i> , 2005 , 46, 541-7	1.9	38
30	Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7565-73	2.2	204
29	Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 676-84	2.2	498
28	Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3768-72	2.2	11
27	The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2005 , 106, 2072-2072	2.2	
26	High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin's Lymphoma.. <i>Blood</i> , 2005 , 106, 2073-2073	2.2	
25	Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2004 , 103, 3684-8	2.2	317
24	Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. <i>British Journal of Haematology</i> , 2004 , 124, 645-52	4.5	118
23	Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2004 , 12, 211-5	1.9	6
22	Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. <i>Blood</i> , 2004 , 103, 1862-8	2.2	84
21	Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. <i>Blood</i> , 2004 , 104, 3483-9	2.2	222
20	Clinical Outcomes and Cost of Outpatient Community-Based Treatment for Rituximab Refractory Non-Hodgkins Lymphoma (NHL) Patients.. <i>Blood</i> , 2004 , 104, 3132-3132	2.2	1
19	Primary Mediastinal Large B Cell Lymphoma: Elucidating Optimal Therapy and Prognostic Factors; an Analysis in 141 Consecutive Patients Treated at Memorial Sloan Kettering from 1980-1999.. <i>Blood</i> , 2004 , 104, 614-614	2.2	4
18	The Importance of Molecular Phenotype in Predicting Overall Survival in Patients with Relapsed or Primary Refractory DLBCL Treated with Second-Line Chemotherapy and ASCT.. <i>Blood</i> , 2004 , 104, 10-10	2.2	1
17	MUC-1 mucin protein expression in B-cell lymphomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2003 , 11, 28-32	1.9	7
16	Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2003 , 102, 1989-96	2.2	210
15	Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. <i>Cancer</i> , 2003 , 98, 1196-205	6.4	128

14	Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1027-35	1.9	100
13	Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma. <i>Oncology</i> , 2003 , 17, 21-6	1.8	4
12	Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. <i>Genes Chromosomes and Cancer</i> , 2002 , 35, 318-28	5	42
11	Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. <i>Blood</i> , 2002 , 99, 2554-61	2.2	43
10	A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. <i>Blood</i> , 2001 , 97, 616-23	2.2	329
9	Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. <i>Blood</i> , 2001 , 97, 1929-36	2.2	19
8	Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. <i>Oncogene</i> , 2001 , 20, 7686-93	9.2	35
7	Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3918-28	2.2	499
6	A novel gene STORP (STOmatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22. <i>European Journal of Haematology</i> , 2000 , 64, 104-13	3.8	6
5	MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. <i>Blood</i> , 2000 , 95, 2930-2936	2.2	48
4	High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. <i>Blood</i> , 2000 , 96, 2399-2404 ^{2,2}		103
3	Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1316-23	2.2	301
2	Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3776-85	2.2	263
1	A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma. <i>Genes Chromosomes and Cancer</i> , 1993 , 6, 140-50 ⁵		18